Stockx L, Wilms G, Baert A L, Terrier F
Department of Radiology, University Hospitals, Leuven, Belgium.
Acta Radiol Suppl. 1996;400:72-4.
The diagnostic efficacy and the clinical tolerance of iobitridol 300 was evaluated in 68 patients receiving intraarterial injection in 2 monocentric comparative randomized double-blind trials with iopromide 300 (30 patients) and iopamidol 300 (40 patients) as reference. RESULTS; There is no significant difference in quality of opacification or in diagnostic efficacy between the products in each trial. No major adverse reactions occurred after the injection of iobitridol 300. Excluding a heat sensation, 5 of the patients who received iobitridol had minor reactions consisting of nausea with vomiting and pain during the injection. Five patients in the reference group also experienced adverse events.
Iobitridol is well tolerated after intraarterial administration and it has the same diagnostic quality as iopromide and iopamidol.
在两项单中心比较随机双盲试验中,以碘普罗胺300(30例患者)和碘帕醇300(40例患者)为对照,评估了300mg碘比醇在68例接受动脉内注射患者中的诊断效能和临床耐受性。结果:在每项试验中,各产品之间在造影剂充盈质量或诊断效能方面无显著差异。注射3l0mg碘比醇后未发生重大不良反应。除有热感外,接受碘比醇的患者中有5例出现轻微反应,包括注射期间恶心伴呕吐和疼痛。参照组的5例患者也发生了不良事件。结论:碘比醇动脉内给药后耐受性良好,其诊断质量与碘普罗胺和碘帕醇相同。